AstraZeneca today announced the company has submitted a New Drug Application to the U.S. FDA and a Marketing Authorisation Application to the European Medicines Agency (EMEA) for an investigational drug,vandetanib 100 mg for use in combination with chemotherapy for the treatment of advanced non-small cell lung cancer in patients previously treated with one prior anti-cancer therapy.
The details can be read here.
No comments:
Post a Comment